Category V Biotech, Inc. (OTC: CATV) is pleased to announce the strategic acquisition of two dynamic companies: FreddyCo, LLC, a New Jersey-based manufacturer of premium hemp-derived products, and Miami FL Distribution, LLC, a Florida-based distribution leader known for delivering the latest, in-demand products across the United States. These acquisitions mark a significant milestone in Category V Biotech’s mission to expand its footprint in the cannabis and wellness sectors, adding robust brands and distribution networks to its growing portfolio.
FreddyCo, LLC is the creator of the popular Rope brand, known for delivering a premium cannabis experience with exceptional quality and potency. This trusted brand stands out for its dedication to providing customers with effective, high-standard products that reflect FreddyCo’s commitment to quality. Consumers and retailers across the industry value Rope for its authentic cannabis experience and proven benefits. More information about FreddyCo and its product offerings is available at www.tryrope.com.
Complementing FreddyCo’s specialized product line, Miami FL Distribution, LLC brings an extensive distribution network and a deep understanding of the latest industry trends. Focused on delivering cutting-edge, differentiated products, Miami FL Distribution serves a broad market, ensuring that stores and wholesalers across Florida and the entire U.S. are stocked with high-demand products that align with consumer preferences and evolving market trends. Their expertise in distribution strengthens CATV’s reach and market impact in both existing and emerging sectors.
“We’re excited to welcome FreddyCo, LLC and Miami FL Distribution, LLC into the Category V Biotech family,” said Michael Feldenkrais, CEO of Category V Biotech, Inc. “This strategic acquisition allows us to offer both the innovation and distribution scale that define success in today’s rapidly growing cannabis and wellness markets. Together, we’re positioned to bring high-quality products to consumers and retailers alike, while meeting evolving consumer demands.”
This acquisition represents Category V Biotech’s continued focus on growth through strategic partnerships and market expansion. With a commitment to quality, innovation, and customer satisfaction, CATV is primed to advance its leadership in the industry.
For additional information, please contact:
Michael Feldenkrais
CEO, Category V Biotech, Inc.
Website: catvbt.com
Email: info@catvbt.com
